August 2026 in “Fabad Journal of Pharmaceutical Sciences” This study developed a Neusilin® US2-based solid self-nanoemulsifying drug delivery system for finasteride that showed improved stability and drug delivery, with complete dissolution comparable to standard Propecia® tablets.
June 2026 in “The Journal of Sexual Medicine” This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.
July 2024 in “Skin Appendage Disorders” This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonal antibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.
April 2023 in “European urology open science” This study reviews the psychological side effects of finasteride, noting a potential association between 5-AR inhibitors and increased depressive symptoms, but emphasizes that the causal link to suicidal ideation remains unclear; the authors recommend mental health screenings and close monitoring for patients starting this medication.
September 2024 in “Medical Sains Jurnal Ilmiah Kefarmasian” This review summarizes the potential of nanostructured lipid carriers in drug delivery systems, highlighting their promise in enhancing the stability and skin penetration of anti-aging cosmetics.